JP4848538B2 - ヒトｃｎｓ神経幹細胞の培養 - Google Patents
ヒトｃｎｓ神経幹細胞の培養 Download PDFInfo
- Publication number
- JP4848538B2 JP4848538B2 JP2000508770A JP2000508770A JP4848538B2 JP 4848538 B2 JP4848538 B2 JP 4848538B2 JP 2000508770 A JP2000508770 A JP 2000508770A JP 2000508770 A JP2000508770 A JP 2000508770A JP 4848538 B2 JP4848538 B2 JP 4848538B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- medium
- neural stem
- stem cells
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000001178 neural stem cell Anatomy 0.000 title claims description 97
- 210000004027 cell Anatomy 0.000 claims description 167
- 210000002569 neuron Anatomy 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 41
- 239000001963 growth medium Substances 0.000 claims description 40
- 239000002609 medium Substances 0.000 claims description 37
- 230000004069 differentiation Effects 0.000 claims description 32
- 238000004113 cell culture Methods 0.000 claims description 28
- 210000004248 oligodendroglia Anatomy 0.000 claims description 25
- 210000002966 serum Anatomy 0.000 claims description 22
- 239000003102 growth factor Substances 0.000 claims description 20
- 210000001130 astrocyte Anatomy 0.000 claims description 19
- 210000003169 central nervous system Anatomy 0.000 claims description 19
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 17
- 230000035755 proliferation Effects 0.000 claims description 13
- 230000002062 proliferating effect Effects 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 8
- 108010046018 leukocyte inhibitory factor Proteins 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000004083 survival effect Effects 0.000 claims description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 7
- 239000007995 HEPES buffer Substances 0.000 claims description 7
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 7
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 6
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 102000008730 Nestin Human genes 0.000 claims description 5
- 108010088225 Nestin Proteins 0.000 claims description 5
- 239000007983 Tris buffer Substances 0.000 claims description 5
- 239000003124 biologic agent Substances 0.000 claims description 5
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 5
- 210000005055 nestin Anatomy 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 4
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
- 229940116977 epidermal growth factor Drugs 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 230000003833 cell viability Effects 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 3
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 239000007993 MOPS buffer Substances 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 239000005700 Putrescine Substances 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- 239000007640 basal medium Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 2
- 239000000186 progesterone Substances 0.000 claims description 2
- 229960003387 progesterone Drugs 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 2
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 claims 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 claims 1
- 101150088952 IGF1 gene Proteins 0.000 claims 1
- 230000000487 effect on differentiation Effects 0.000 claims 1
- 230000000431 effect on proliferation Effects 0.000 claims 1
- 229940116978 human epidermal growth factor Drugs 0.000 claims 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 claims 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 29
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 29
- 210000000130 stem cell Anatomy 0.000 description 24
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 23
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 21
- 238000002054 transplantation Methods 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 14
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 14
- 230000012010 growth Effects 0.000 description 14
- 238000010186 staining Methods 0.000 description 14
- 239000003226 mitogen Substances 0.000 description 13
- 210000004129 prosencephalon Anatomy 0.000 description 13
- 238000001890 transfection Methods 0.000 description 13
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 11
- 208000023105 Huntington disease Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 239000010432 diamond Substances 0.000 description 11
- 230000001537 neural effect Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 10
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 102000004243 Tubulin Human genes 0.000 description 8
- 108090000704 Tubulin Proteins 0.000 description 8
- 208000036815 beta tubulin Diseases 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 6
- 229950004398 broxuridine Drugs 0.000 description 6
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 210000001577 neostriatum Anatomy 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 229920002866 paraformaldehyde Polymers 0.000 description 6
- 108010055896 polyornithine Proteins 0.000 description 6
- 229920002714 polyornithine Polymers 0.000 description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 6
- 101710128836 Large T antigen Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 235000011010 calcium phosphates Nutrition 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000012239 gene modification Methods 0.000 description 5
- 230000005017 genetic modification Effects 0.000 description 5
- 235000013617 genetically modified food Nutrition 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 102100028652 Gamma-enolase Human genes 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 230000003492 excitotoxic effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000002518 glial effect Effects 0.000 description 4
- 239000012120 mounting media Substances 0.000 description 4
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 3
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001111320 Homo sapiens Nestin Proteins 0.000 description 3
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000004695 Polyether sulfone Substances 0.000 description 3
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- -1 and 1% serum Substances 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 101150022753 galc gene Proteins 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 102000043377 human NES Human genes 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229920006393 polyether sulfone Polymers 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 2
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- 102000008763 Neurofilament Proteins Human genes 0.000 description 2
- 108010088373 Neurofilament Proteins Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003210 demyelinating effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 210000002451 diencephalon Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 231100000318 excitotoxic Toxicity 0.000 description 2
- 231100000063 excitotoxicity Toxicity 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000002165 glioblast Anatomy 0.000 description 2
- 210000004295 hippocampal neuron Anatomy 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000005044 neurofilament Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100038778 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 108091008604 NGF receptors Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 231100000876 cognitive deterioration Toxicity 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000501 collagen implant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 229940078064 cyclosporine injection Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000009034 developmental inhibition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000000142 dyskinetic effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 102000046645 human LIF Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000535 oligodendrocyte precursor cell Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000004205 output neuron Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000004725 selective neuronal vulnerability Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
- C12N2501/392—Sexual steroids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/926,313 US5968829A (en) | 1997-09-05 | 1997-09-05 | Human CNS neural stem cells |
| US08/926,313 | 1997-09-05 | ||
| PCT/US1998/018597 WO1999011758A2 (en) | 1997-09-05 | 1998-09-04 | Cultures of human cns neural stem cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008331441A Division JP2009106301A (ja) | 1997-09-05 | 2008-12-25 | ヒトｃｎｓ神経幹細胞の培養 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002518990A JP2002518990A (ja) | 2002-07-02 |
| JP2002518990A5 JP2002518990A5 (enExample) | 2006-01-05 |
| JP4848538B2 true JP4848538B2 (ja) | 2011-12-28 |
Family
ID=25453045
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000508770A Expired - Fee Related JP4848538B2 (ja) | 1997-09-05 | 1998-09-04 | ヒトｃｎｓ神経幹細胞の培養 |
| JP2008331441A Pending JP2009106301A (ja) | 1997-09-05 | 2008-12-25 | ヒトｃｎｓ神経幹細胞の培養 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008331441A Pending JP2009106301A (ja) | 1997-09-05 | 2008-12-25 | ヒトｃｎｓ神経幹細胞の培養 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US5968829A (enExample) |
| EP (1) | EP1007636B1 (enExample) |
| JP (2) | JP4848538B2 (enExample) |
| AU (1) | AU758270B2 (enExample) |
| CA (1) | CA2302484C (enExample) |
| WO (1) | WO1999011758A2 (enExample) |
Families Citing this family (238)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7544511B2 (en) | 1996-09-25 | 2009-06-09 | Neuralstem Biopharmaceuticals Ltd. | Stable neural stem cell line methods |
| US5968829A (en) * | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US6093531A (en) * | 1997-09-29 | 2000-07-25 | Neurospheres Holdings Ltd. | Generation of hematopoietic cells from multipotent neural stem cells |
| US5958767A (en) * | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
| US7410798B2 (en) * | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| US20020168766A1 (en) * | 2000-01-11 | 2002-11-14 | Gold Joseph D. | Genetically altered human pluripotent stem cells |
| US6667176B1 (en) * | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US6488930B1 (en) * | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
| US7217565B2 (en) * | 1999-02-12 | 2007-05-15 | Stemcells California, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| US7037719B1 (en) | 1999-02-12 | 2006-05-02 | Stemcells California, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| US6468794B1 (en) | 1999-02-12 | 2002-10-22 | Stemcells, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| US7105150B2 (en) * | 1999-02-12 | 2006-09-12 | Stemcells California, Inc. | In vivo screening methods using enriched neural stem cells |
| ES2295012T3 (es) * | 1999-02-12 | 2008-04-16 | Stemcells California, Inc. | Poblaciones enriquecidas de celulas del sistema nervioso central. |
| JP2002538820A (ja) * | 1999-03-17 | 2002-11-19 | ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレイション | ミクロクローンのクローニングされていないｃＤＮＡライブラリーの作製および使用 |
| EP1161523A4 (en) * | 1999-03-18 | 2003-04-02 | Wellstat Biologics Corp | CELLS, CELL POPULATIONS, AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US20090047325A1 (en) * | 1999-04-30 | 2009-02-19 | Neurotrophincell Pty. Limited | Xenotransplant for cns therapy |
| US20050265977A1 (en) * | 1999-04-30 | 2005-12-01 | Elliott Robert B | Xenotransplant for CNS therapy |
| ATE468122T1 (de) * | 1999-04-30 | 2010-06-15 | Neurotrophincell Pty Ltd | Xenotransplant für zns therapie |
| US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| US8609412B2 (en) | 1999-08-05 | 2013-12-17 | Regents Of The University Of Minnesota | Mapc generation of lung tissue |
| JP5398941B2 (ja) * | 1999-08-05 | 2014-01-29 | エイビーティー ホールディング カンパニー | 多能性成体幹細胞およびそれを単離する方法 |
| US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
| US6749850B1 (en) | 1999-08-18 | 2004-06-15 | The General Hospital Corporation | Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| WO2001028574A2 (en) * | 1999-10-20 | 2001-04-26 | Stem Cells, Inc. | Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain |
| US6878543B1 (en) * | 1999-10-25 | 2005-04-12 | Nsgene Sa | Cultures of GFAP+ nestin+ cells that differentiate to neurons |
| CA2393071A1 (en) * | 1999-12-07 | 2001-06-14 | Monash University | Long-term cell culture compositions and genetically modified animals derived therefrom |
| AU779273B2 (en) * | 1999-12-07 | 2005-01-13 | Monash University | Long-term cell culture compositions and genetically modified animals derived therefrom |
| EP1107003A1 (en) * | 1999-12-09 | 2001-06-13 | Trophos | Methods for screening compounds active on neurons |
| AU2913801A (en) * | 1999-12-23 | 2001-07-03 | Cornell Research Foundation Inc. | A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
| US7455983B2 (en) * | 2000-01-11 | 2008-11-25 | Geron Corporation | Medium for growing human embryonic stem cells |
| US20050042749A1 (en) * | 2001-05-16 | 2005-02-24 | Carpenter Melissa K. | Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease |
| EP1248640B1 (en) * | 2000-01-20 | 2006-10-04 | Diabcell Pty Limited | Preparation and xenotransplantation of porcine islets |
| AU3499801A (en) * | 2000-02-11 | 2001-08-20 | Schepens Eye Res Inst | Isolation and transplantation of retinal stem cells |
| US20030162700A1 (en) * | 2000-03-03 | 2003-08-28 | Shipham Kylie Ann-Maree | Method of treatment |
| US7011828B2 (en) * | 2000-03-14 | 2006-03-14 | Es Cell International Pte. Ltd. | Implanting neural progenitor cells derived for human embryonic stem cells |
| WO2001068815A1 (en) | 2000-03-14 | 2001-09-20 | Es Cell International Pte Ltd | Embryonic stem cells and neural progenitor cells derived therefrom |
| WO2001078752A2 (en) | 2000-04-13 | 2001-10-25 | Board Of Regents, The University Of Texas System | Treatment of disorders by implanting stem cells and/or progeny thereof into gastrointestinal organs |
| US7037493B2 (en) | 2000-05-01 | 2006-05-02 | Cornell Research Foundation, Inc. | Method of inducing neuronal production in the brain and spinal cord |
| US6828145B2 (en) | 2000-05-10 | 2004-12-07 | Cedars-Sinai Medical Center | Method for the isolation of stem cells by immuno-labeling with HLA/MHC gene product marker |
| AU6319901A (en) * | 2000-05-17 | 2001-11-26 | Geron Corp | Neural progenitor cell populations |
| US7250294B2 (en) * | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
| US6897061B1 (en) | 2000-06-16 | 2005-05-24 | Spinal Cord Society | Transdifferentiation of glial cells |
| US6602680B2 (en) | 2000-07-14 | 2003-08-05 | The Regents Of The University Of California | Production of gabaergic cells |
| ES2386505T3 (es) * | 2000-10-17 | 2012-08-22 | Diatranz Otsuka Limited | Preparación y xenotrasplante de islotes de cerdo |
| AU3929402A (en) * | 2000-11-22 | 2002-06-11 | Geron Corp | Tolerizing allografts of pluripotent stem cells |
| US6921665B2 (en) | 2000-11-27 | 2005-07-26 | Roslin Institute (Edinburgh) | Selective antibody targeting of undifferentiated stem cells |
| US6576464B2 (en) | 2000-11-27 | 2003-06-10 | Geron Corporation | Methods for providing differentiated stem cells |
| US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| EP2305795B1 (en) | 2000-12-06 | 2019-07-03 | Celularity, Inc. | Method of collecting placental stem cells |
| WO2002064755A2 (en) * | 2001-02-14 | 2002-08-22 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| JP2004529621A (ja) | 2001-02-14 | 2004-09-30 | ティー ファークト，レオ | 多能性成体幹細胞、その起源、それを得る方法および維持する方法、それを分化させる方法、その使用法、ならびにそれ由来の細胞 |
| WO2002069976A2 (en) * | 2001-03-02 | 2002-09-12 | Stem Cell Therapeutics Inc. | Use of ovarian hormone for increasing neural stem cell number |
| WO2002076206A2 (en) * | 2001-03-23 | 2002-10-03 | University Of Ottawa | Methods and compositions for cryopreservation of dissociated primary animal cells |
| JP3763749B2 (ja) * | 2001-03-28 | 2006-04-05 | 独立行政法人科学技術振興機構 | 脊髄におけるシナプス形成ニューロンを誘導する中枢神経系前駆細胞 |
| US7838292B1 (en) * | 2001-03-29 | 2010-11-23 | University Of Louisville Research Foundation, Inc. | Methods for obtaining adult human olfactory progenitor cells |
| US20020169102A1 (en) * | 2001-04-03 | 2002-11-14 | Frey William H. | Intranasal delivery of agents for regulating development of implanted cells in the CNS |
| EP1385938A1 (en) * | 2001-04-23 | 2004-02-04 | Nsgene A/S | Method and culture medium for producing neural cells expressing tyrosine hydroxylase |
| US7943376B2 (en) | 2001-04-27 | 2011-05-17 | Stem Cell Therapuetics Inc. | Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells |
| AU2002315336A1 (en) * | 2001-06-18 | 2003-01-02 | Psychiatric Genomics, Inc. | Method for neural stem cell differentiation using 5ht-1a agonists |
| US7132286B2 (en) * | 2001-06-18 | 2006-11-07 | Psychiatric Genomics, Inc. | Method for neural stem cell differentiation using valproate |
| WO2003000852A2 (en) * | 2001-06-22 | 2003-01-03 | The University Of Texas System | Method of producing region-specific neurons from human neuronal stem cells |
| CN1549924A (zh) * | 2001-07-16 | 2004-11-24 | �����ʸ���˹�ع�˾ | 通过等电点分析生物分子的缓冲液的阵列 |
| DE60233805D1 (de) * | 2001-08-08 | 2009-11-05 | Levesque Biosciences Inc | Zusammensetzungen und verfahren zur isolierung, vermehrung und differenzierung nicht-embryonale menschlicher stammzellen und deren verwendungen |
| WO2003014320A2 (en) * | 2001-08-10 | 2003-02-20 | Cornell Research Foundation, Inc. | Telomerase immortalized human neutral stem cells and phenotypically-restricted progenitor cells |
| US20050042746A1 (en) * | 2001-09-28 | 2005-02-24 | Olga Garkavenko | Growing xenotransplant material in culture |
| EP1448053A4 (en) * | 2001-10-02 | 2005-03-09 | Becton Dickinson Co | PROLIFERATION AND DIFFERENTIATION OF STEM CELLS BY EXTRACELLULAR MATRIX AND OTHER MOLECULES |
| US7588937B2 (en) * | 2001-10-03 | 2009-09-15 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
| US8153424B2 (en) * | 2001-10-03 | 2012-04-10 | Wisconsin Alumni Research Foundation | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
| US7129034B2 (en) * | 2001-10-25 | 2006-10-31 | Cedars-Sinai Medical Center | Differentiation of whole bone marrow |
| NZ515310A (en) * | 2001-11-07 | 2004-08-27 | Diabcell Pty Ltd | Methods of treatment and delivery modes |
| CA2466578A1 (en) * | 2001-11-15 | 2003-05-30 | Becton, Dickinson And Company | Methods and devices for the integrated discovery of cell culture environments |
| WO2003060085A2 (en) * | 2002-01-14 | 2003-07-24 | The Board Of Trustees Of The University Of Illinois | Mammalian neural stem cells, compositions and uses thereof |
| US7576065B2 (en) * | 2002-02-15 | 2009-08-18 | Cornell Research Foundation, Inc. | Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein |
| US20040029269A1 (en) * | 2002-05-07 | 2004-02-12 | Goldman Steven A | Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells |
| US7285415B2 (en) | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| US20050101014A1 (en) * | 2002-07-11 | 2005-05-12 | Keirstead Hans S. | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| CA2493849A1 (en) * | 2002-07-12 | 2004-01-22 | University Of Washington | Methods and systems for extended in vitro culture of neuronal cells |
| AU2003247135A1 (en) * | 2002-07-23 | 2004-02-09 | Nanodiagnostics, Inc. | Embryonic stem cell markers and uses thereof |
| WO2007116408A2 (en) * | 2006-04-11 | 2007-10-18 | Nanodiagnostics Israel Ltd. | Pluripotent stem cells characterized by expression of germline specific genes |
| AU2003276924A1 (en) * | 2002-09-25 | 2004-04-19 | Bresagen, Inc. | Compositions and methods for enrichment of neural stem cells using ceramide analogs |
| AU2003273332A1 (en) * | 2002-09-26 | 2004-04-19 | Children's Medical Center Corporation | Method of enhancing proliferation and/or hematopoietic differentiation of stem cells |
| US20040147020A1 (en) * | 2002-11-01 | 2004-07-29 | The Regents Of The University Of Colorado, A Body Corporate | Dopamine neurons from human embryonic stem cells |
| US20050265983A1 (en) * | 2002-11-17 | 2005-12-01 | Eldad Melamed | Methods, nucleic acid constructs and cells for treating neurodegenerative disorders |
| DK1583541T3 (da) * | 2002-11-20 | 2011-04-11 | Neuronova Ab | Forbindelser og fremgangsmåder til at øge neurogenese |
| CA2505534A1 (en) | 2002-11-26 | 2004-06-10 | Anthrogenesis Corporation | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
| US20060134078A1 (en) * | 2002-12-02 | 2006-06-22 | Anges Mg, Inc. | Method for culturing neural stem cells using hepatocyte growth factor |
| EP1576134B1 (en) | 2002-12-09 | 2013-03-06 | Judith Kelleher-Andersson | Method for discovering neurogenic agents |
| US8293488B2 (en) | 2002-12-09 | 2012-10-23 | Neuralstem, Inc. | Method for screening neurogenic agents |
| AU2003303741A1 (en) * | 2002-12-18 | 2004-09-17 | Bresagen, Inc. | Compositions and methods for neural cell production and stabilization |
| ATE446791T1 (de) | 2003-05-16 | 2009-11-15 | Univ Laval | Cns chlorid-modulierung und verwendung derselben |
| AU2004320466A1 (en) * | 2003-06-11 | 2006-02-02 | Jan Remmereit | Nuclear reprogramming of cells for therapeutic use |
| ES2584428T3 (es) | 2003-06-20 | 2016-09-27 | Axiogenesis Ag | Modelado de tejidos en un sistema de células madre embrionarias (ES) |
| CA2529573A1 (en) * | 2003-06-24 | 2004-12-29 | Diabcell Pty Limited | Porcine islets cultured with porcine sertoli cells for xenotransplantation |
| WO2005003320A2 (en) | 2003-07-02 | 2005-01-13 | Regents Of The University Of Minnesota | Neuronal differentiation of stem cells |
| EP1644485B9 (en) | 2003-07-08 | 2012-01-04 | Axiogenesis Ag | Secreted proteins as markers for cell differentiation |
| WO2005026343A1 (ja) * | 2003-09-09 | 2005-03-24 | Keio University | 神経幹細胞の生存及び／又は増殖及び神経突起伸張を促進する方法並びに促進剤、神経幹細胞を含む医薬組成物、検定方法、スクリーニング方法 |
| CA2537960C (en) * | 2003-09-12 | 2012-01-10 | Stemcell Technologies Inc. | Neural colony forming assay |
| WO2005033297A1 (en) * | 2003-09-19 | 2005-04-14 | The Rockefeller University | Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells |
| EP1670897A4 (en) * | 2003-09-24 | 2008-02-27 | Univ Leland Stanford Junior | IGF-1 FORM OF NERVOUS STEM CELLS OF THE CENTRAL NERVOUS SYSTEM ADULTS PLURIPOTENT TO AN OLIGODENDROGICAL LINE |
| JP2005139164A (ja) * | 2003-11-10 | 2005-06-02 | Toudai Tlo Ltd | 神経障害及び神経変性疾患を治療するための薬学的組成物 |
| ES2579804T3 (es) * | 2003-12-02 | 2016-08-16 | Celavie Biosciences, Llc | Composiciones y métodos para la propagación de células progenitoras neurales |
| US20070269412A1 (en) * | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
| US20050196864A1 (en) * | 2004-02-10 | 2005-09-08 | Goldman Steven A. | Induction and high-yield preparative purification of mesencephalic dopaminergic neuronal progenitor cells and dopaminergic neurons from human embryonic stem cells |
| WO2005079250A2 (en) * | 2004-02-13 | 2005-09-01 | Cornell Research Foundation, Inc. | Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom |
| CN101080486B (zh) | 2004-04-23 | 2012-05-16 | 佰欧益股份有限公司 | 多谱系祖细胞 |
| US7622108B2 (en) | 2004-04-23 | 2009-11-24 | Bioe, Inc. | Multi-lineage progenitor cells |
| US8785187B2 (en) * | 2004-06-09 | 2014-07-22 | The University Court Of The University Of Edinburgh | Neural stem cells |
| ATE373081T1 (de) | 2004-09-30 | 2007-09-15 | Reneuron Ltd | Zelllinie |
| JP5424559B2 (ja) | 2004-11-17 | 2014-02-26 | ニューラルステム・インコーポレーテッド | 神経変性状態を治療するためのヒト神経細胞の移植 |
| US20090010873A1 (en) * | 2004-11-29 | 2009-01-08 | Yeda Research And Development Co. Ltd. | Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis |
| US7629169B2 (en) | 2004-12-01 | 2009-12-08 | Stem Cell Therapeutics Corp. | Methods for the production of platelet-derived growth factor-responsive neural precursor cells |
| US7018804B1 (en) | 2004-12-03 | 2006-03-28 | Orion Biosolutions, Inc. | Determination of cell viability and phenotype |
| US20060121443A1 (en) * | 2004-12-03 | 2006-06-08 | Orion Biosolutions, Inc. | Determination of cell viability |
| AU2006203879A1 (en) * | 2005-01-04 | 2006-07-13 | Stemcells California, Inc. | Methods for the treatment of lysosomal storage disorders |
| CN101155912A (zh) * | 2005-01-31 | 2008-04-02 | 同源治疗公司 | 显示出内皮细胞特征的脂肪来源的成年基质细胞 |
| NZ540597A (en) * | 2005-06-08 | 2007-02-23 | Neurotrophincell Pty Ltd | A method for preventing the onset of type I diabetes comprising administering an implantable composition comprising living choroid plexus cells |
| ES2524996T3 (es) | 2005-06-16 | 2014-12-16 | Ramot At Tel Aviv University Ltd. | Células aisladas y poblaciones que comprenden a las mismas para el tratamiento de enfermedades del SNC |
| CN101233226B (zh) * | 2005-06-22 | 2017-08-11 | 阿斯特利亚斯生物治疗股份公司 | 人胚胎干细胞的悬浮培养物 |
| SG163588A1 (en) * | 2005-07-08 | 2010-08-30 | Braincells Inc | Methods for identifying agents and conditions that modulate neurogenesis |
| TW200726474A (en) * | 2005-07-15 | 2007-07-16 | Cognate Therapeutics Inc | The immunophenotype and immunogenicity of human adipose derived cells |
| WO2007013771A1 (en) * | 2005-07-28 | 2007-02-01 | Brainguard Co., Ltd. | Carbon nanotubes serving as stem cell scaffold |
| US8357666B2 (en) * | 2005-08-01 | 2013-01-22 | Nupotential, Inc. | Reprogramming a cell by inducing a pluripotent gene through RNA interference |
| US9095573B2 (en) * | 2005-08-01 | 2015-08-04 | University Of Central Florida Research Foundation, Inc. | Method of biasing implanted human neural stem cells away from differentiation into glial cells by (+)phenserine to modulate the concentration of soluble βAPP in tissue or CSF |
| WO2008020815A1 (en) | 2006-08-15 | 2008-02-21 | Agency For Science, Technology And Research | Mesenchymal stem cell conditioned medium |
| EP1957633B1 (en) | 2005-10-13 | 2013-12-18 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
| ATE517178T1 (de) * | 2005-11-17 | 2011-08-15 | Cleveland Clinic Foundation | Multipotente neurale stammzellen |
| US7803364B2 (en) | 2005-11-17 | 2010-09-28 | The Cleveland Clinic Foundation | Multipotent neural stem cells |
| EP2471903B1 (en) | 2005-12-29 | 2018-02-14 | Anthrogenesis Corporation | Placental stem cell populations |
| WO2007079184A2 (en) | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
| NZ571127A (en) | 2006-03-07 | 2012-01-12 | Geeta Shroff | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation |
| CA2647246C (en) * | 2006-03-30 | 2015-06-23 | Research Foundation Of City University Of New York | Stimulation of neuron regeneration by secretory leukocyte protease inhibitor |
| WO2007121443A2 (en) | 2006-04-17 | 2007-10-25 | Bioe, Inc. | Differentiation of multi-lineage progenitor cells to respiratory epithelial cells |
| US8557295B2 (en) | 2006-05-11 | 2013-10-15 | Regenics As | Use of cellular extracts for skin rejuvenation |
| WO2008020329A2 (en) | 2006-05-11 | 2008-02-21 | Regenics As | Administration of cells and cellular extracts for rejuvenation |
| US8877253B2 (en) * | 2006-05-11 | 2014-11-04 | Regenics As | Cellular extracts |
| US20080003676A1 (en) * | 2006-06-26 | 2008-01-03 | Millipore Corporation | Growth of embryonic stem cells |
| EP2049043B1 (en) * | 2006-07-24 | 2018-10-10 | International Stem Cell Corporation | Synthetic cornea from retinal stem cells |
| WO2008027848A2 (en) * | 2006-08-31 | 2008-03-06 | The University Of Louisville Research Foundation, Inc. | Transcription factors for differentiation of adult human olfactory progenitor cells |
| US8685720B2 (en) | 2006-11-03 | 2014-04-01 | The Trustees Of Princeton University | Engineered cellular pathways for programmed autoregulation of differentiation |
| EP3960764A1 (en) | 2006-11-03 | 2022-03-02 | The Board of Trustees of the Leland Stanford Junior University | Selective immunodepletion of endogenous stem cell niche for engraftment |
| US9005964B2 (en) | 2006-11-24 | 2015-04-14 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
| US20090136456A1 (en) * | 2006-12-22 | 2009-05-28 | Yadong Huang | Methods of treating neurodegenerative disorders |
| PL2120977T3 (pl) | 2007-02-12 | 2013-12-31 | Anthrogenesis Corp | Leczenie chorób zapalnych z zastosowaniem łożyskowych komórek macierzystych |
| US20080213892A1 (en) * | 2007-03-02 | 2008-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Self-renewal of neural stem cells is promoted by wnt proteins |
| US20080226707A1 (en) * | 2007-03-05 | 2008-09-18 | Jill Helms | WNT compositions and methods of use thereof |
| EP2136646A1 (en) * | 2007-03-08 | 2009-12-30 | Raymond F. Sekula Jr. | A method of producing purified neural stem cells and related methods of treating a patient |
| US20100196328A1 (en) * | 2007-04-25 | 2010-08-05 | Tonya Bliss | ISCHEMIA-INDUCED NEOVASCULARIZATION IS ENHANCED BY hCNS-SC TRANSPLANTATION |
| WO2008132722A1 (en) | 2007-04-26 | 2008-11-06 | Ramot At Tel-Aviv University Ltd. | Pluripotent autologous stem cells from oral mucosa and methods of use |
| WO2009015343A2 (en) * | 2007-07-25 | 2009-01-29 | Bioe, Inc. | Differentiation of multi-lineage progenitor cells to chondrocytes |
| US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
| EP2028268A1 (en) | 2007-08-20 | 2009-02-25 | Université Libre De Bruxelles | Generation of neuronal cells from pluripotent stem cells |
| EP2192916A4 (en) * | 2007-08-23 | 2012-04-04 | Univ Leland Stanford Junior | MODULATION OF SYNAPTOGENESIS |
| PT2194121T (pt) | 2007-09-11 | 2016-12-05 | Univ Sapporo Medical | Método de proliferação celular e agente farmacêutico para reparação e regeneração de tecidos |
| US8263065B2 (en) | 2007-09-28 | 2012-09-11 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| US20090090214A1 (en) * | 2007-10-04 | 2009-04-09 | Chung Yuan Christian University | Method for forming nano-scale metal particles |
| SG188096A1 (en) * | 2008-01-30 | 2013-03-28 | Geron Corp | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
| EP2271747B1 (en) | 2008-03-17 | 2016-09-07 | Agency for Science, Technology And Research | Microcarriers for pluripotent stem cell culture |
| EP2276838A4 (en) | 2008-04-07 | 2012-02-01 | Nupotential Inc | RE-PROGRAMMING A CELL BY INDUCING A PLURIPOTENTIC GENE THROUGH RNA INTERFERENCE |
| EP2294187A2 (en) * | 2008-05-21 | 2011-03-16 | BioE LLC | Differentiation of multi-lineage progenitor cells to pancreatic cells |
| DK2285951T3 (en) | 2008-05-28 | 2018-10-22 | Univ Ramot | TREATMENT OF CNS DISEASES OF CNS DISEASES |
| US8669048B2 (en) * | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
| EP3172963B1 (en) | 2008-08-20 | 2019-02-06 | Celularity, Inc. | Improved cell composition and methods of making the same |
| DK2329012T3 (da) | 2008-08-20 | 2020-08-24 | Celularity Inc | Behandling af slagtilfælde under anvendelse af isolerede placentaceller |
| DK2331109T3 (da) | 2008-08-22 | 2013-09-08 | Anthrogenesis Corp | Fremgangsmåder og sammensætninger til behandling af knogledefekter med placentale cellepopulationer |
| RU2562154C2 (ru) | 2008-11-19 | 2015-09-10 | Антродженезис Корпорейшн | Амниотические адгезивные клетки |
| GB0822246D0 (en) | 2008-12-05 | 2009-01-14 | Reneuron Ltd | Composition |
| EP3187581A1 (en) | 2008-12-23 | 2017-07-05 | BOCO Silicon Valley, Inc. | Target populations of oligodendrocyte precursor cells and methods of making and using same |
| US10041040B2 (en) | 2009-02-03 | 2018-08-07 | Keio University | Culture method of embryoid bodies and/or neural stem cells derived from human differentiated cell-derived pluripotent stem cells |
| GB0902034D0 (en) * | 2009-02-06 | 2009-03-11 | Reneuron Ltd | Method |
| US9101570B1 (en) | 2009-02-13 | 2015-08-11 | Endocellutions, Inc. | Adult and neonatal stem cell therapy to treat diabetes through the repair of the gastrointestinal tract |
| US20100209399A1 (en) * | 2009-02-13 | 2010-08-19 | Celavie Biosciences, Llc | Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects |
| WO2010111278A1 (en) | 2009-03-23 | 2010-09-30 | The Texas A&M University System | Compositions of mesenchymal stem cells to regenerate bone |
| JP5783504B2 (ja) * | 2009-03-30 | 2015-09-24 | 国立研究開発法人国立環境研究所 | 胎生プログラミングに対する影響を評価するための方法 |
| MX2011011718A (es) | 2009-05-08 | 2012-01-27 | Vaccinex Inc | Anticuerpos anti-cd100 y metodos para su uso. |
| EP3190179A1 (en) | 2009-07-02 | 2017-07-12 | Anthrogenesis Corporation | Method of producing erythrocytes without feeder cells |
| ES2690199T3 (es) | 2009-07-21 | 2018-11-19 | Abt Holding Company | Uso de células madre para reducir la extravasación de leucocitos |
| EP3831930A1 (en) | 2009-07-21 | 2021-06-09 | ABT Holding Company | Use of stem cells to reduce leukocyte extravasation |
| KR101747983B1 (ko) | 2009-08-22 | 2017-06-15 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 배아, 난모세포, 그리고 줄기 세포의 이미징과 평가 |
| CN102725399B (zh) | 2009-12-18 | 2015-03-11 | 上海赛傲生物技术有限公司 | 制备多能干细胞的材料和方法 |
| KR20120115602A (ko) | 2010-01-26 | 2012-10-18 | 안트로제네시스 코포레이션 | 태반 줄기 세포를 사용한 골 관련 암의 치료 |
| US8927276B2 (en) * | 2010-02-17 | 2015-01-06 | Cellin Technologies Oue | Ex vivo progenitor and stem cell expansion and differentiation for use in the treatment of disease of the nervous system |
| SG183497A1 (en) | 2010-02-25 | 2012-09-27 | Abt Holding Co | Modulation of macrophage activation |
| PT2556145T (pt) | 2010-04-07 | 2016-10-25 | Anthrogenesis Corp | Angiogénese usando células estaminais placentárias |
| EP2555783A1 (en) | 2010-04-08 | 2013-02-13 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
| HUE040278T2 (hu) | 2010-04-23 | 2019-02-28 | Cold Spring Harbor Laboratory | Új szerkezetileg tervezett shRNS-ek |
| KR20230096132A (ko) | 2010-07-13 | 2023-06-29 | 셀룰래리티 인코포레이티드 | 천연 킬러 세포의 생성 방법 |
| MX341316B (es) | 2010-07-28 | 2016-08-15 | Neuralstem Inc * | Poblacion de celulas madre neurales para tratar y/o revertir enfermedades y/o trastornos neurodegenerativos. |
| CA2807226A1 (en) | 2010-08-19 | 2012-02-23 | F.Hoffmann-La Roche Ag | Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs) |
| WO2012034070A1 (en) | 2010-09-09 | 2012-03-15 | The Board Of Trustees Of The Leland Stanford Junior University | Use of liposomal wnt compositions to enhance osseointegration |
| US9677042B2 (en) | 2010-10-08 | 2017-06-13 | Terumo Bct, Inc. | Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
| US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
| EP2670426B1 (en) | 2011-01-31 | 2017-05-10 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
| JP2014507664A (ja) | 2011-02-23 | 2014-03-27 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ヒト胚における異数性の検出方法 |
| WO2012164137A1 (es) | 2011-05-30 | 2012-12-06 | Fundación Investigación En Regeneración Del Sistema Nervioso | Células madre y células de la estirpe neural derivadas de la glía envolvente olfatoria, y sus aplicaciones |
| US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
| SG10201914092XA (en) | 2011-06-06 | 2020-03-30 | ReGenesys BVBA | Expansion of stem cells in hollow fiber bioreactors |
| US20130046093A1 (en) * | 2011-08-18 | 2013-02-21 | Korea Institute Of Science And Technology | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same |
| US9925221B2 (en) | 2011-09-09 | 2018-03-27 | Celularity, Inc. | Treatment of amyotrophic lateral sclerosis using placental stem cells |
| DK2766093T3 (en) | 2011-10-11 | 2018-06-06 | Vaccinex Inc | USE OF SEMAPHORIN-4D BINDING MOLECULES FOR MODULATING THE PERMEABILITY OF THE BLOOD-BRAIN BARRIER |
| EP2782587B1 (en) | 2011-11-21 | 2018-11-07 | Ramot at Tel Aviv University, Ltd. | Stem cell-derived neural cells for cell therapy in neurological disorders |
| EP2814947B1 (en) | 2012-02-17 | 2018-11-21 | Schepens Eye Research Institute | Phenotype profile of human retinal progenitor cells |
| CN102604894B (zh) * | 2012-02-29 | 2014-07-30 | 中国科学院广州生物医药与健康研究院 | 用于制备神经干细胞的培养基及其用途 |
| GB201302468D0 (en) | 2013-02-12 | 2013-03-27 | Reneuron Ltd | Stem cell product |
| JP6450673B2 (ja) | 2012-04-03 | 2019-01-09 | リニューロン・リミテッドＲｅＮｅｕｒｏｎ Ｌｉｍｉｔｅｄ | 幹細胞微粒子 |
| MX359004B (es) * | 2012-04-18 | 2018-09-12 | K Stemcell Co Ltd | Método para la fabricación de células madre que tienen tamaño apropiado para administración intravascular. |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| ES2717478T3 (es) | 2012-05-31 | 2019-06-21 | Ares Trading Sa | Métodos de predicción de blastocistos embrionarios in vitro |
| KR101523040B1 (ko) * | 2012-06-26 | 2015-05-26 | 라정찬 | 고농도의 줄기세포 제조방법 |
| US20150164955A1 (en) | 2012-07-19 | 2015-06-18 | Reneuron Limited | Stem cell microparticles |
| US9605074B2 (en) | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
| US10357517B1 (en) | 2012-10-01 | 2019-07-23 | University Of South Florida | Methods of treating epilepsy using neural stem cells that express nanog, SSEA-4, OCT-4, MIR-34B, MIR-34C and MIR-592 |
| EP3459522B1 (en) | 2012-12-10 | 2021-02-17 | Regenics AS | Use of egg cellular extracts for wound treatment |
| US10241108B2 (en) | 2013-02-01 | 2019-03-26 | Ares Trading S.A. | Abnormal syngamy phenotypes observed with time lapse imaging for early identification of embryos with lower development potential |
| JP2016506968A (ja) | 2013-02-05 | 2016-03-07 | アントフロゲネシス コーポレーション | 胎盤由来のナチュラルキラー細胞 |
| US20160002597A1 (en) | 2013-02-12 | 2016-01-07 | Reneuron Limited | Method of producing microparticles |
| EP3795159A1 (en) | 2013-04-12 | 2021-03-24 | Houston Methodist Hospital | Improving organs for transplantation |
| ES2753323T3 (es) | 2013-04-30 | 2020-04-08 | Univ Leuven Kath | Terapia celular para síndromes mielodisplásicos |
| GB201317887D0 (en) | 2013-10-09 | 2013-11-20 | Reneuron Ltd | Product |
| GB201317889D0 (en) | 2013-10-09 | 2013-11-20 | Reneuron Ltd | Product and use |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| EP3068867B1 (en) | 2013-11-16 | 2018-04-18 | Terumo BCT, Inc. | Expanding cells in a bioreactor |
| WO2015140005A1 (en) | 2014-03-19 | 2015-09-24 | Ifom Fondazione Istituto Firc Di Oncologia Molecolare | Method of generation of pluripotent cells |
| ES2837840T3 (es) | 2014-03-20 | 2021-07-01 | Ares Trading Sa | Medida cuantitativa de la cinética de desarrollo de la morfología de mórula y blastocisto humanos |
| EP4257145B1 (en) | 2014-08-26 | 2025-06-25 | The Board of Trustees of the Leland Stanford Junior University | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling |
| CA2964927C (en) | 2014-10-20 | 2019-07-30 | Neuralstem, Inc. | Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof |
| EP4008775A1 (en) | 2015-03-04 | 2022-06-08 | Mesoblast International Sàrl | Cell culture method for mesenchymal stem cells |
| US11827904B2 (en) | 2015-04-29 | 2023-11-28 | Fred Hutchinson Cancer Center | Modified stem cells and uses thereof |
| CN105420105B (zh) * | 2015-12-25 | 2017-11-17 | 北京工业大学 | 生物芯片及其制造方法 |
| WO2017153982A1 (en) | 2016-03-06 | 2017-09-14 | Yeda Research And Development Co. Ltd. | Method for modulating myelination |
| US10513689B2 (en) | 2016-04-29 | 2019-12-24 | Hope Biosciences, Llc | Culture media for multipotent stem cells |
| WO2018140940A1 (en) | 2017-01-30 | 2018-08-02 | The Board Of Trustees Of The Leland Stanford Junior University | A non-genotoxic conditioning regimen for stem cell transplantation |
| JP7695192B2 (ja) | 2018-10-08 | 2025-06-18 | アレン インスティテュート | 介在ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物 |
| GB201919021D0 (en) | 2019-12-20 | 2020-02-05 | Reneuron Ltd | Nucleic acid constructs for delivering polynucleotides into exosomes |
| EP4127138A1 (en) | 2020-03-30 | 2023-02-08 | King Abdullah University Of Science And Technology | Compositions and methods for controlling cellular identity |
| CN112080470B (zh) * | 2020-09-14 | 2022-07-12 | 中国科学院遗传与发育生物学研究所 | 一种神经干细胞向神经元分化的体外培养方法 |
| EP4200404A4 (en) | 2020-10-22 | 2025-01-01 | The Regents of University of California | DEVICES AND METHODS FOR ASSESSING THE VIABILITY OF EMBRYOS |
| GB202114441D0 (en) | 2021-10-08 | 2021-11-24 | Reneuron Ltd | Proteins and extracellular vesicles |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996015226A1 (en) * | 1994-11-14 | 1996-05-23 | Neurospheres Holdings Ltd. | Regulation of neural stem cell proliferation |
| WO1997016534A1 (en) * | 1995-11-01 | 1997-05-09 | Genentech, Inc. | Normal neural epithelial precursor cells |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4753635A (en) * | 1986-05-23 | 1988-06-28 | Jacqueline Sagen | Inducing analgesia by implantation of cells releasing neuroactive substances |
| NZ226750A (en) * | 1987-10-29 | 1990-09-26 | Amrad Corp Ltd | Immortalisation of neural precursor cells by introducing a retrovirus vector containing a myc-oncogene |
| US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
| US4980174A (en) * | 1988-12-23 | 1990-12-25 | Jacqueline Sagen | Method for alleviating depression |
| WO1991002003A1 (en) * | 1989-08-04 | 1991-02-21 | Board Of Regents, The University Of Texas System | Methods and compositions; purified preparation of neural progenitor regulatory factor |
| US5411883A (en) * | 1989-12-26 | 1995-05-02 | Somatix Therapy Corporation | Proliferated neuron progenitor cell product and process |
| WO1991009936A1 (en) * | 1989-12-26 | 1991-07-11 | Hana Biologics, Inc. | Proliferated neuron progenitor cell product and process |
| GB9003791D0 (en) * | 1990-02-20 | 1990-04-18 | Ludwig Inst Cancer Res | Transgenic animals,cell lines therefrom,and their use |
| JPH05507909A (ja) * | 1990-04-26 | 1993-11-11 | シェリング・コーポレーション | Ｎ―置換アミノ酸および誘導体のジアステレオ選択的製造法 |
| US5612211A (en) * | 1990-06-08 | 1997-03-18 | New York University | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors |
| US5750376A (en) * | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| EP0594669B9 (en) * | 1991-07-08 | 2008-03-19 | NeuroSpheres Holdings Ltd. | Growth factor-responsive neural progenitor cells which can be proliferated in vitro. |
| US5851832A (en) * | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
| US5980885A (en) * | 1991-07-08 | 1999-11-09 | Neurospheres Holdings Ltd. | Growth factor-induced proliferation of neural precursor cells in vivo |
| US5175103A (en) * | 1991-10-21 | 1992-12-29 | Trustees Of University Of Pennsylvania | Preparation of pure cultures of post-mitotic human neurons |
| JP4101284B2 (ja) * | 1991-11-22 | 2008-06-18 | ジェネンテック・インコーポレーテッド | 神経損傷を改善するｔｇｆ−ｂｅｔａ |
| US5672499A (en) * | 1992-07-27 | 1997-09-30 | California Institute Of Technology | Immoralized neural crest stem cells and methods of making |
| AU683023B2 (en) * | 1992-10-16 | 1997-10-30 | Neurospheres Holdings Ltd | Remyelination using neural stem cells |
| ES2194016T5 (es) * | 1992-10-28 | 2007-11-16 | Neurospheres Holdings Ltd. | Factores biologicos y celulas germinales neurales. |
| US5766948A (en) | 1993-01-06 | 1998-06-16 | The Regents Of The University Of California | Method for production of neuroblasts |
| ES2218524T3 (es) * | 1993-01-29 | 2004-11-16 | Neurospheres Holdings Ltd. | Modificacion genetica de celulas primordiales neurales. |
| US5405772A (en) * | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
| US5639618A (en) | 1994-05-13 | 1997-06-17 | Plurion, Inc. | Method of isolating a lineage specific stem cell in vitro |
| CA2200709A1 (en) * | 1994-09-23 | 1996-03-28 | Samuel Weis | In vitro models of cns function and dysfunction |
| JP2997995B2 (ja) | 1995-09-13 | 2000-01-11 | 日本コーンスターチ株式会社 | 生分解性樹脂組成物の水系分散液 |
| US5753506A (en) * | 1996-05-23 | 1998-05-19 | Cns Stem Cell Technology, Inc. | Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals |
| US5968829A (en) * | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
-
1997
- 1997-09-05 US US08/926,313 patent/US5968829A/en not_active Expired - Lifetime
-
1998
- 1998-09-04 CA CA2302484A patent/CA2302484C/en not_active Expired - Fee Related
- 1998-09-04 AU AU93059/98A patent/AU758270B2/en not_active Ceased
- 1998-09-04 US US09/486,302 patent/US6498018B1/en not_active Expired - Lifetime
- 1998-09-04 JP JP2000508770A patent/JP4848538B2/ja not_active Expired - Fee Related
- 1998-09-04 WO PCT/US1998/018597 patent/WO1999011758A2/en not_active Ceased
- 1998-09-04 EP EP98945920.1A patent/EP1007636B1/en not_active Expired - Lifetime
- 1998-10-23 US US09/178,035 patent/US6103530A/en not_active Expired - Lifetime
-
2002
- 2002-04-29 US US10/134,234 patent/US6777233B2/en not_active Expired - Lifetime
-
2006
- 2006-02-15 US US11/356,281 patent/US20060240553A1/en not_active Abandoned
-
2007
- 2007-09-21 US US11/903,408 patent/US20080107633A1/en not_active Abandoned
-
2008
- 2008-12-25 JP JP2008331441A patent/JP2009106301A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996015226A1 (en) * | 1994-11-14 | 1996-05-23 | Neurospheres Holdings Ltd. | Regulation of neural stem cell proliferation |
| WO1997016534A1 (en) * | 1995-11-01 | 1997-05-09 | Genentech, Inc. | Normal neural epithelial precursor cells |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1007636A2 (en) | 2000-06-14 |
| US5968829A (en) | 1999-10-19 |
| US20080107633A1 (en) | 2008-05-08 |
| US20020164309A1 (en) | 2002-11-07 |
| WO1999011758A3 (en) | 1999-05-27 |
| US6103530A (en) | 2000-08-15 |
| US6777233B2 (en) | 2004-08-17 |
| CA2302484A1 (en) | 1999-03-11 |
| EP1007636B1 (en) | 2014-06-18 |
| JP2009106301A (ja) | 2009-05-21 |
| US6498018B1 (en) | 2002-12-24 |
| WO1999011758A2 (en) | 1999-03-11 |
| AU9305998A (en) | 1999-03-22 |
| AU758270B2 (en) | 2003-03-20 |
| CA2302484C (en) | 2013-12-24 |
| JP2002518990A (ja) | 2002-07-02 |
| US20060240553A1 (en) | 2006-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4848538B2 (ja) | ヒトｃｎｓ神経幹細胞の培養 | |
| AU755657B2 (en) | Lineage-restricted neuronal precursors | |
| US20030118566A1 (en) | Compositions and methods for isolation, propagation, and differentiation of human stem cells and uses thereof | |
| US20080138895A1 (en) | Cultures of gfap+ nestin+ cells that differentiate to neurons | |
| US20090087851A1 (en) | Lineage-Restricted Neuronal Precursors | |
| US20030166276A1 (en) | Cultures of human CNS neural stem cells | |
| EP1749088A2 (en) | Expansion of neural stem cells with lif | |
| WO2006055841A2 (en) | Indefinite culture of human adult glia without immortalization and therapeutic uses thereof | |
| JP2003512333A (ja) | 脳における移植された前駆体細胞のインビボ増殖および移動を誘導するための方法 | |
| US20040103448A1 (en) | Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain | |
| KR20100061794A (ko) | 경동맥체로부터 유래된 줄기세포 및 이의 용도 | |
| MXPA00000225A (en) | Lineage-restricted neuronal precursors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050829 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050829 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081024 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081225 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100325 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100624 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100701 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100707 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110601 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110817 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110831 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110926 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110927 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110926 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141028 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |